SCI Pharmtech Inc (4119) - Total Liabilities
Based on the latest financial reports, SCI Pharmtech Inc (4119) has total liabilities worth NT$1.62 Billion TWD (≈ $50.88 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 4119 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
SCI Pharmtech Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how SCI Pharmtech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is SCI Pharmtech Inc's balance sheet.
SCI Pharmtech Inc Competitors by Total Liabilities
The table below lists competitors of SCI Pharmtech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
STI Co. Ltd
KQ:039440
|
Korea | ₩58.65 Billion |
|
BF Utilities Limited
NSE:BFUTILITIE
|
India | Rs-11.71 Billion |
|
Limoneira Co
NASDAQ:LMNR
|
USA | $130.12 Million |
|
Azkoyen
MC:AZK
|
Spain | €71.89 Million |
|
Celon Pharma SA
WAR:CLN
|
Poland | zł141.95 Million |
|
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
NASDAQ:OACC
|
USA | $8.64 Million |
|
EMS Limited
NSE:EMSLIMITED
|
India | Rs2.72 Billion |
|
S H Kelkar and Company Limited
NSE:SHK
|
India | Rs-13.62 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down SCI Pharmtech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SCI Pharmtech Inc (4119) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SCI Pharmtech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SCI Pharmtech Inc (2002–2025)
The table below shows the annual total liabilities of SCI Pharmtech Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.49 Billion ≈ $47.02 Million |
-13.43% |
| 2024-12-31 | NT$1.72 Billion ≈ $54.31 Million |
+8.36% |
| 2023-12-31 | NT$1.59 Billion ≈ $50.12 Million |
+19.49% |
| 2022-12-31 | NT$1.33 Billion ≈ $41.94 Million |
+53.15% |
| 2021-12-31 | NT$869.26 Million ≈ $27.39 Million |
-30.33% |
| 2020-12-31 | NT$1.25 Billion ≈ $39.31 Million |
+105.61% |
| 2019-12-31 | NT$606.84 Million ≈ $19.12 Million |
+4.84% |
| 2018-12-31 | NT$578.85 Million ≈ $18.24 Million |
+58.21% |
| 2017-12-31 | NT$365.88 Million ≈ $11.53 Million |
-23.68% |
| 2016-12-31 | NT$479.43 Million ≈ $15.10 Million |
-31.02% |
| 2015-12-31 | NT$695.02 Million ≈ $21.90 Million |
-30.12% |
| 2014-12-31 | NT$994.64 Million ≈ $31.34 Million |
+1.02% |
| 2013-12-31 | NT$984.62 Million ≈ $31.02 Million |
+206.62% |
| 2012-12-31 | NT$321.12 Million ≈ $10.12 Million |
-16.65% |
| 2011-12-31 | NT$385.26 Million ≈ $12.14 Million |
+3.18% |
| 2010-12-31 | NT$373.37 Million ≈ $11.76 Million |
+74.21% |
| 2009-12-31 | NT$214.32 Million ≈ $6.75 Million |
+12.71% |
| 2008-12-31 | NT$190.16 Million ≈ $5.99 Million |
+7.59% |
| 2007-12-31 | NT$176.74 Million ≈ $5.57 Million |
+86.14% |
| 2006-12-31 | NT$94.94 Million ≈ $2.99 Million |
-26.42% |
| 2004-12-31 | NT$129.03 Million ≈ $4.07 Million |
+25.28% |
| 2003-12-31 | NT$102.99 Million ≈ $3.24 Million |
-60.04% |
| 2002-12-31 | NT$257.76 Million ≈ $8.12 Million |
-- |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more